Skip to main content

Table 1 Basic clinical information of HCC patients

From: Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression

Clinical feature

All(N = 60)

Age

58(32–76)

Gender

 

57(95%)

3 (5%)

ECOG

 

0

42(70%)

1

18(30%)

HBV

 

Yes

45(75%)

No

15(25%)

AFP

 

≥ 400

18(30%)

< 400

42(70%)

Differentiation

 

Moderate

18(30%)

Moderate-poor

18(30%)

Poor

24(40%)

Effect

 

CR

1 (2%)

PR

18(30%)

SD

30(50%)

PD

11(18%)

GPC3 expression

 

Negative

12(20%)

Weakly positive

18(30%)

Moderate positive

13(22%)

Strongly positive

17(28%)